Innovative healthcare consulting company to implement
Smart Vital Sign technology
Los Angeles, CA., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce that Keto Holdings, LLC (“Keto”) has joined the Draganfly reseller program and is taking initial delivery of Smart Vital technology assessment units.
Keto provides healthcare-based consulting services to multiple industries including pharmaceutical, food processing, nursing home and travel. Keto is working with several high-profile clients to roll out Draganfly’s Vital Intelligence platform.
Draganfly’s Vital Intelligence assessment station and screening technology is quick and non-invasive (contactless). The stations can automatically detect elevated body temperature and, with voluntary consent, heart rate, respiratory rate and O2 saturation, all from a camera that takes seconds to capture the information. Draganfly’s Vital Intelligence platform has several delivery capabilities including an API for 3rd party developers to integrate the technology with their own apps and devices.
“We are looking forward to ensuring that the industries which we serve have the latest technology to help assess potential cases of Covid-19,” said Brett Louderback, Founder and Executive Director of Keto. “Draganfly’s commitment to providing the most up to date, secure and accurate vital signs screening available makes them the ideal solution for our customer base.”
“We are incredibly excited to be providing Keto the latest in our Smart Vital Sign technology which they will implement across the multiple industries they work with,” said Cameron Chell, CEO of Draganfly.
The Company also announces that it has completed an initial closing of its previously announced Regulation A+ offering (the “Offering”) of units of the Company (“Units”). The Company issued 2,556,496 Units at price of US$0.47 per Unit for gross proceeds in the amount of US$1,201,553 in this first closing. Each Unit is comprised of one common share of the Company (“Common Share”) and one Common Share purchase warrant (“Warrant”), with each Warrant entitling the holder to acquire one Common Share at a price of US$0.71 per Common Share until November 30, 2022. The Common Shares and Warrants issued in connection with the Offering are subject to a nine month hold period which will expire on August 30, 2021.
About Draganfly
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge and software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.
Media Contact
Arian Hopkins
email: media@draganfly.com
Company Contact
Email: info@draganfly.com
Forward-Looking Statements
This news release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements include, but are not limited to, statements with respect the successful use of the Vital Intelligence technology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.